Sionna Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript
Good morning, everyone, and thank you for joining us. It's my pleasure to introduce the Sionna team. With us, we have Mike Cloonan, President and CEO; and Charlotte McKee, Chief Medical Officer.
Questions & Answers
Mike, Sionna is sitting ahead of first proof-of-concept data from its NBD1 stabilizer approach in cystic fibrosis, which is expected this summer. In this context, how is the company positioned data-wise over the next 12 months?
Yeah, well, first, Salveen, thanks for having us. It's great to be here with you. Thank you, Goldman, for hosting us as well.
And yes, so as we think about -- you've just hit on the head. We're really focused right now on that summer of 2026, as you articulated. We have two different data readouts happening in the summer of 2026. We have our Phase 2a proof-of-concept
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
